A global leader in medical technology Medtronic provides solutions for people with chronic disease. The company offers products, therapies and services to enhance or extend the lives of millions of patients. Medtronic's technology is used to treat conditions such as diabetes, heart disease, neurological disorders, and vascular illnesses.
Medtronic’s key business areas include:
Cardiac Rhythm Disease Management – products for managing cardiac rhythm disorders to improve long-term patient care.
Neuromodulation, Spinal, and ENT Surgery - products include neurostimulation systems, drug delivery systems, neurosurgical implant devices, surgical access products, diagnostic and therapeutic systems for chronic pain, neurologic, urologic, and gastrointestinal disorders, and surgical instruments for treating ear, nose, throat and eye disorders and diseases.
CardioVascular - products and therapies for coronary artery, vascular, and structural heart disease.
Medtronic receives CE Mark for valve-in-valve (VIV) procedures using the CoreValve and CoreValve Evolut transcatheter aortic valve implantation (TAVI) systems in degenerated bioprosthetic surgical aortic valves.
Medtronic reveals new data demonstrating that simultaneously pacing the lower chambers of the heart, or biventricular (BiV) pacing with a cardiac resynchronization therapy (CRT) device, improves heart failure symptoms and quality of life in a subset of heart failure patients.
Medtronic receives US Food and Drug Administration (FDA) approval for the company's newest cardiac devices:
the Viva portfolio of cardiac resynchronization therapy with defibrillation (CRT-D) devices, and the Evera portfolio of implantable cardioverter-defibrillators (ICD).
Medtronic is entering into an innovative partnership with the National Institute of Hospital Administration, a think tank under China's National Health and Family Planning Commission, to carry out a series of research projects focusing on building an integrated care pathway for patients with Type 1 diabetes.
Medtronic is releasing the CardioGuide Implant System, a novel real-time navigation system for cardiac resynchronization therapy pacemakers and defibrillators (CRT-P and CRT-D), in the United States and Canada.
Medtronic receives the CE Mark for the Engager Transcatheter Aortic Valve Implantation (TAVI) System with transapical delivery catheter to treat patients with severe aortic stenosis who are at high or extreme risk for surgical aortic valve replacement (SAVR).
Medtronic receives Japanese regulatory approval and plans to launch the Advisa DR MRI SureScan pacing system which is the first and only MR-Conditional pacemaker available to patients in Japan, the world's second largest market for medical devices.
Medtronic receives 510(k) clearance from the Food and Drug Administration (FDA) for the Aquamantys 3 BSC 9.1S Bipolar Sealer with Cutting, a new addition to the orthopaedic portfolio of the company's Advanced Energy business.
The Resolute drug-eluting stent (DES) from Medtronic is shown in a new study to yields strong performance in coronary artery disease (CAD) patients both with and without diabetes through two years of follow-up.
Medtronic's Resolute Integrity Coronary Stent System receives European regulatory approval for several new indications, making it the drug-eluting stent (DES) with the broadest range of approved indications in Europe.
Medtronic reveals findings from an economic analysis of the landmark RAFT (Resynchronization/Defibrillation in Ambulatory Heart Failure Trial) trial demonstrating that cardiac resynchronization therapy with defibrillation (CRT-D) is a cost-effective treatment for mildly symptomatic heart failure patients.
Medtronic is reporting six month pooled outcomes from randomized and crossover patients in the Symplicity HTN-2 clinical trial following renal denervation with the Symplicity renal denervation system showing significant, sustained blood pressure reduction in patients with treatment-resistant hypertension.
Medtronic reveals results of a double-blind, randomized study, ISSUE-3, which found that patients who suffered from fainting due to neurocardiogenic syncope had fewer fainting occurrences when treated with a Medtronic pacemaker.
Medtronic receives the CE Mark for the CD HORIZON BalanC Spinal System and is launching the product internationally to expand the options for physicians outside the United States in treating multi-level spinal surgeries requiring fusion at one or more levels and neutral stabilization (non fusion) at an adjacent level for common spine conditions such as spinal stenosis and early stage degenerative disc disease.
A patient from Kempenhaeghe-Heeze in The Netherlands is the first patient to be enrolled into the MORE (MedtrOnic Registry for Epilepsy) Registry which is designed to look at the long-term efficacy, quality of life impact and safety of deep brain stimulation (DBS) in patients with refractory epilepsy.
A patient from Kempenhaeghe-Heeze (The Netherlands) is the first patient to be enrolled into the MORE (MedtrOnic Registry for Epilepsy) Registry which is designed to look at the long-term efficacy, quality of life impact and safety of deep brain stimulation (DBS) in patients with refractory epilepsy.
In the next step toward the development of an artificial pancreas, Medtronic, reports results of the in-clinic ASPIRE (Automation to Simulate Pancreatic Insulin REsponse) study have been published online and in the March edition of Diabetes Technology and Therapeutics.
Medtronic is entering into an exclusive distribution agreement with Miami Instruments - a company focused on the design of innovative surgical instruments for minimally invasive cardiac surgery (MICS) procedures – and has introduced the company's first two products in the USA.
The first patient is enrolled in the FIRE AND ICE clinical trial, which is a prospective, randomized, multinational head-to-head clinical trial comparing the long-term safety, effectiveness and ease of use of the Medtronic Arctic Front Cardiac CryoAblation System compared to the Biosense Webster CARTO System Guided THERMOCOOL Catheter to treat patients with symptomatic paroxysmal atrial fibrillation.
Medtronic completes patient enrollment in the extreme risk study in its CoreValve US Pivotal Trial and the company has also received approval from the US Food and Drug Administration (FDA) for an extended investigation (under the FDA's Continued Access Policy) to continue enrolling extreme risk patients under a Continued Access Study protocol.
Medtronic receives 510(k) clearance from the Food and Drug Administration (FDA) for the Aquamantys SBS 5.0 Sheathed Bipolar Sealer, a new addition to the spine portfolio of the company's Advanced Energy business.
Medtronic receives the CE mark for the Endurant II AAA Stent Graft System and is making the international launch of the system which meaningfully expands the options physicians outside the USA have to treat patients with abdominal aortic aneurysms through a minimally invasive technique called endovascular aortic repair (EVAR).
Medtronic receives US Food and Drug Administration approval and US market launch of the first-of-its-kind mySentry Remote Glucose Monitor, which allows a parent or caregiver to monitor from another room a patient's MiniMed Paradigm REAL-Time Revel System.
Medtronic receives Food and Drug Administration (FDA) approval of iPro2, a next generation Professional continuous glucose monitoring (CGM) system and the latest in a series of recent diabetes technology approvals and innovations from the company.
The US Food and Drug Administration (FDA) approval of Medtronic's AdaptiveStim with RestoreSensor neurostimulation system, the first and only chronic pain treatment that harnesses motion sensor technology found in smart phones and computer gaming systems to provide effective pain relief and convenience by automatically adapting stimulation levels to the needs of people with chronic back and/or leg pain.
Medtronic receives US Food and Drug Administration (FDA) approval of its AdaptiveStim with RestoreSensor neurostimulation system, the first chronic pain treatment that harnesses motion sensor technology found in smart phones and computer gaming systems to provide effective pain relief and convenience by automatically adapting stimulation levels to the needs of people with chronic back and/or leg pain.
Medtronic is reporting results of an retrospective study available online and in an upcoming print edition of the Journal of Spinal Disorders and Techniques that demonstrates the effectiveness of the Aquamantys System in limiting blood loss and reducing transfusions during spinal corrective surgery.
Medtronic receives US Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) to conduct a pivotal in-home clinical trial protocol for the ASPIRE study of the MiniMed Paradigm System featuring Low Glucose Suspend (LGS) automation.
Medtronic starts SYMPLICITY HTN-3, the company's US clinical trial of the Symplicity Renal Denervation System for treatment-resistant hypertension. The first patient in this landmark study was enrolled at the Prairie Heart Institute at St John's Hospital in Springfield, Illinois, USA.
Medtronic is reporting results from its Tailored Treatment of Permanent Atrial Fibrillation (TTOP-AF) clinical trial, the first randomized study comparing ablation therapy with the Medtronic Phased RF Ablation System ablation system to traditional medical management (antiarrhythmic drugs and direct current
cardioversion) in 210 patients with persistent or long-standing persistent atrial fibrillation (AF).